Drug intelligence / Profile preview

VTC-880

Development stage: Unknown
Lead developer: Virtici
Modality: Peptides
Administration: Intrahepatic Portal Vein Infusion

Overview

VTC-880 is a novel peptide treatment candidate being developed by Virtici LLC. It is currently in Phase 2 development, supported by a Phase 2 Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the NIH. The drug is intended for the treatment of periodontitis.

Targets

P. gingivalis (Porphyromonas gingivalis)

Beyond the preview

Go deeper on VTC-880.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTC-880.

Explore the full profile